“We are very optimistic about our technology’s promise and plan to launch our first in-human trial in 2022.” ![]() “Argá Medtech gives physicians an unparalleled ability to perform much more flexible, elegant ablation procedures, likely improving outcomes and reducing the need for repeat surgeries and saving costs for both hospitals and the healthcare system,” said Neale. These advantages offer the potential to improve precision, speed, safety and efficiency in cardiac ablation procedures while reducing procedure costs. Its design enables the catheter to take different shapes allowing for the creation of circular, linear or focal lesions. Argá’s new CSE system allows physicians to select all bipolar, all unipolar or combinations of bipolar and unipolar energy delivery modes to titrate the lesion to the needs of the patient.Īrgá Medtech’s catheter also offers unmatched flexibility in its ability to perform any lesion type necessary for the patient’s treatment of AF, eliminating the need to use additional ablation catheters. It is imperative to develop new tools that improve success rates while lowering procedure costs.”Īrgá Medtech’s unique CSE PFA platform offers several advantages over other PFA technologies, which are powered mostly by a square wave energy source. “While the cardiac ablation field has achieved major progress in treating AF, outcomes have only marginally improved in the past 15 years, and costs have increased. “AF affects 37.5 million people worldwide 1, significantly raising their chances of a stroke or heart attack and greatly diminishing their quality of life,” said David Neale, CEO and co-founder of Argá Medtech. The company’s CSE Pulsed Field Ablation (PFA) offers unmatched flexibility in treating atrial fibrillation (AF) with its proprietary CSE generator and a multi-configurable catheter. ![]() ![]() LAUSANNE, Switzerland and SAN DIEGO, Ap(GLOBE NEWSWIRE) - Argá Medtech, a company developing Coherent Sine-Burst Electroporation (CSE), a next-generation non-thermal cardiac ablation system for treating cardiac arrhythmias, announced a featured poster presentation on preliminary findings for its innovative technology at the 2022 Annual Meeting of the Heart Rhythm Society (HRS), April 29 to May 1 in San Francisco. Preliminary feasibility study results demonstrate the company’s Coherent Sine-Burst Electroporation (CSE) Pulsed Field Ablation platform’s ability to titrate lesion depth using sinusoidal waveforms.Argá Medtech’s next-generation non-thermal cardiac ablation system shows promise in improving precision, speed and flexibility in treating atrial fibrillation.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |